Introduction
============

Gastric cancer (GC) is one of the most common malignant tumors of the digestive system. The 2018 Global Cancer Report shows that more than half of the 18.1 million new cancer cases and 9.6 million cancer-related deaths worldwide occur in Asia. GC ranks as the sixth most common newly diagnosed cancer, with an incidence of 5.7%; however, the mortality rate is as high as 8.2%, second only to mortality due to lung cancer ([@b1-mco-0-0-1980]). Although comprehensive treatment based on surgery in recent years has further improved the treatment of patients with GC, the overall prognosis of patients with GC is still poor ([@b2-mco-0-0-1980],[@b3-mco-0-0-1980]). Therefore, it is particularly important to effectively predict the survival of patients with GC and to develop individualized treatment options. In the past, combined with the comprehensive evaluation of intraoperative and postoperative pathology, tumor biomarkers, such as the pathological stage, depth of invasion, number of involved lymph nodes, and presence or absence of surrounding tissues, are the key factors used to determined the prognosis of patients ([@b4-mco-0-0-1980]). However, the prognosis of patients with GC is related not only to tumor biomarkers but also to the body\'s inflammation and immunity.

In recent years, the importance of preoperative nutritional status and immunity in patients with GC has been recognized ([@b5-mco-0-0-1980],[@b6-mco-0-0-1980]). The preoperative nutritional status and immunity of patients with GC determine whether the patient can undergo surgery and are some of the important factors in the evaluation of postoperative complications, postoperative recurrence and metastasis, chemotherapy tolerance and long-term prognosis ([@b7-mco-0-0-1980]). Li *et al* ([@b11-mco-0-0-1980]) showed that the implementation of effective preoperative nutrition and immune supportive treatments can improve the quality of life and long-term prognosis of patients with GC. The prognostic nutritional index (PNI) is a simple and convenient indicator for assessing preoperative nutritional status and immunity in patients ([@b12-mco-0-0-1980]). In recent years, it has been used for the clinical evaluation of prognosis in patients with a variety of cancers. However, few studies have explored the value of the preoperative PNI compared with the value of traditional inflammatory markers in the prognosis of patients after GC radical surgery. This study investigated the value of the preoperative PNI compared with the value of traditional inflammatory indicators in the prognostic evaluation of patients undergoing GC radical surgery to provide a reference for clinical diagnosis and treatment.

Patients and methods
====================

### Patients

We retrospectively assessed all patients with resectable GC who were treated between January 1, 2010, and January 15, 2013, at the Department of Gastrointestinal Surgery of The First Affiliated Hospital of Bengbu Medical College (Bengbu, China). The following inclusion criteria were applied: i) GC was preoperatively confirmed by pathology and histopathology; ii) patient had not undergone neoadjuvant radiotherapy and chemotherapy before surgery; iii) had no infectious diseases before blood collection; iv) was confirmed by imaging to have no distant metastasis; v) patient underwent radical gastrectomy; vi) follow-up occurred during or after March, and vii) patient died of GC or gastric cancer-related diseases. The following exclusion criteria were applied: i) Patient could not tolerate surgery due to severe liver and kidney dysfunction; ii) had an active infection; iii) had autoimmune disease; iv) had other malignant tumors and end-stage diseases, and v) patient was missing clinical data. Finally, 170 patients were included in the study. Clinical data, such as sex, age, recent weight loss, histological type, tumor location, tumor size, TNM stage, and pathological stage, were collected. The results of the first blood collection of patients admitted to the hospital included neutrophil count, lymphocyte count, monocyte count, and serum albumin concentration. The NLR, LMR, and PNI were calculated. The NLR was calculated as the neutrophil count divided by the lymphocyte count. The LMR was calculated as the lymphocyte count divided by the monocyte count. The PNI was equal to the serum albumin (g/L) + 5^\*^ lymphocyte absolute count (10^9^/L) ([@b12-mco-0-0-1980]). Surgical procedures were performed according to the Japanese Gastric Cancer Treatment Guidelines ([@b13-mco-0-0-1980]). The pathological staging of all enrolled patients was performed according to the eighth edition of the AJCC guidelines for histopathological findings ([@b14-mco-0-0-1980]). This study was approved by the Ethics Committee of the First Affiliated Hospital of Bengbu Medical College. All patients provided signed informed consent.

### Follow-up

All patients were followed up with a regular clinical visit and by telephone. A postoperative follow-up assessment was performed every 3 months for 5 years and then every 6 months during years 3-5. Follow-up included a physical examination; laboratory and imaging examinations; laboratory tests, including routine blood tests, routine biochemical tests, and tumor markers; and imaging examinations, including a chest X-ray and an enhanced abdominal CT examination. The clinical follow-up time was from the date of surgery to the time of death or the deadline, which was December 2018.

### Statistical analysis

Data analysis was performed using SPSS Statistics 23.0 software (ver. 23.0; IBM Corp.). Measurement data were expressed as mean ± SD. Differences between groups were analyzed by one-way analysis of variance (ANOVA) and Student\'s t-tests. The χ^2^ test was used to compare the count data, and Fisher\'s exact test was used when the sample size was \<5. The diagnostic value of each inflammatory index for cancer-related death 5 years after radical gastrectomy was analyzed by receiver operating characteristic (ROC) curve analysis. The areas under the curves and the Z values were compared to determine the discriminatory ability of each inflammatory index. The overall survival (OS) time was the number of days from the day of surgery until the day of death. The survival rate was expressed by the Kaplan-Meier curve, and the log-rank χ^2^ test was used for comparison between the groups. Multivariate analysis of the 5 year survival rate after GC surgery was performed with the Cox proportional hazard regression model. All statistical tests were bilateral, and the significance was set to P\<0.05.

Results
=======

### The ROC curve was used to determine the cut-off value

The areas under the PNI, NLR, and LMR curves were 0.725, 0.609 and 0.609, respectively. When the PNI was 46.030, the Youden index was at the maximum, with a sensitivity of 77.14% and a specificity of 69.69%. When the NLR was 2.464, the Youden index was at the maximum, with a sensitivity of 80.00% and a specificity of 45.93%. When the LMR was 3.279, the Youden index was at the maximum, with a sensitivity of 80.00% and a specificity of 48.15%. In addition, the ROC curve showed that the area under the PNI curve was 0.725, which was significantly higher than those of the NLR and LMR (P\<0.05) ([Fig. 1](#f1-mco-0-0-1980){ref-type="fig"} and [Table I](#tI-mco-0-0-1980){ref-type="table"}).

### Clinicopathological characteristics

The general clinical features of 170 patients with GC are shown in [Table II](#tII-mco-0-0-1980){ref-type="table"}. There were 127 males and 43 females. The average age of the patients was 61.14±11.47 years old. The most common pathological type of tumor was adenocarcinoma, and the most common tumor site was the cardia. With regard to TNM staging, there were 15 patients with T1-T2 tumors, 155 patients with T3-T4 tumors, 77 patients with N0-N1 tumors, 93 patients with N2-N3 tumors, 53 patients with phase I/II tumors, and 117 patients with phase III tumors. PNI was significantly associated with sex, histological type, tumor size, N stage, pathological stage, the NLR, and the LMR (P\<0.05) ([Table II](#tII-mco-0-0-1980){ref-type="table"}).

### Subsistence analysis

The average follow-up time for the entire group was 31.7 months (4.6-107.5) months. The postoperative survival rate of patients with PNI \<46.03 was significantly lower than that of patients with PNI ≥46.03 (23.7 months vs. 34.3 months, log-rank χ^2^=19.700, P\<0.001) ([Fig. 2](#f2-mco-0-0-1980){ref-type="fig"}).

### Univariate analysis and multivariate analysis of postoperative survival in gastric cancer

Univariate analysis showed that tumor location, tumor size, T stage, N stage, pathological stage, the NLR, the LMR, and the PNI may be risk factors for survival after GC radical resection (P\<0.01). The significant results obtained by univariate analysis were included in the Cox regression model. Finally, T3-T4 stage (HR=5.267; 95% CI, 1.878-14.770), N2-N3 stage (HR=1.731; 95% CI, 1.036-2.895), pathological grade III (HR=8.386; 95% CI, 4.415-15.929) and PNI≥46.03 (HR=1.513; 95% CI, 1.015-2.256) were identified as independent risk factors affecting the survival of GC patients after radical surgery ([Table III](#tIII-mco-0-0-1980){ref-type="table"}).

Discussion
==========

GC has been attracting attention in the academic community due to its high morbidity and mortality rates ([@b1-mco-0-0-1980]). Although surgery has improved the 5 year survival rate of patients with GC, the prognosis is still not optimistic. Gullo *et al* ([@b15-mco-0-0-1980]) showed that the prognosis of GC as a highly heterogeneous tumor is closely related to many factors. In addition to the traditional TNM staging system, it is also closely related to the body\'s immunity, inflammation, and nutrition.

Most patients with GC suffer from nausea, vomiting, abdominal pain, abdominal distension and other symptoms that affect the appetite and diet of the patient. On the other hand, the rapid growth of malignant tumor cells causes the body to consume a large amount of nutrients, resulting in the lack of the synthesis of nutrients, which causes tumor necrosis and the production of toxic substances, leading to metabolic disorders in the body. Therefore, most patients often have different degrees of malnutrition at the time of treatment ([@b16-mco-0-0-1980],[@b17-mco-0-0-1980]). Malnutrition can lead to the loss of optimal treatment timing for patients and the need to delay treatment, which can lead to disease progression. In addition, malnutrition leads to decreased T cell function and the deterioration of the intestinal environment, further aggravating the progression of tumor-associated inflammation ([@b18-mco-0-0-1980]). In 1863, since Virchow first proposed the association between inflammation and cancer, the role of inflammation in tumorigenesis, tumor development and metastasis has been continuously explored ([@b19-mco-0-0-1980]). Mantovani *et al* ([@b20-mco-0-0-1980]) showed that tumor-associated inflammation is characterized by the swelling of inflammatory cells and the production and release of inflammatory factors in tumor tissues. Inflammatory cells and immune cells, such as neutrophils, lymphocytes, and monocytes, in the peripheral blood of patients with tumor-associated inflammation are considered to be important factors leading to tumor development, invasion and metastasis ([@b21-mco-0-0-1980]). Existing studies have shown that the NLR and LMR play important roles in determining the prognosis of cancer patients ([@b25-mco-0-0-1980]).

The PNI was first established by Japanese scholars and was originally used to assess the preoperative nutritional status, surgical risk and postoperative complications in surgical patients ([@b12-mco-0-0-1980]). The PNI is calculated as an indicator of the nutritional status of the body and is based on the level of serum albumin and the number of lymphocytes ([@b12-mco-0-0-1980]). As the main component of plasma protein, serum albumin plays an important role in maintaining the colloid osmotic pressure of the body; on the other hand, it can also reflect the nutritional status of the body. Ouyang *et al* ([@b28-mco-0-0-1980]) showed that preoperative serum albumin levels are associated with prognosis in patients with GC. The immune response of lymphocytes to the tumor has been gradually applied to the prognostic evaluation of tumor patients in recent years ([@b29-mco-0-0-1980]). The PNI has been used recently for the prognostic evaluation of various tumors, including colorectal cancer ([@b30-mco-0-0-1980]), liver cancer ([@b31-mco-0-0-1980]), and pancreatic cancer ([@b32-mco-0-0-1980]).

Our results show that the preoperative PNI is superior to traditional inflammatory markers for the evaluation of prognosis after GC radical surgery. This may be because the preoperative PNI (in contrast with the traditional inflammatory indicators: The NLR and LMR) can reflect the nutritional status of the body and the body\'s inflammatory and immune response. A high preoperative PNI and good OS in GC patients suggest that active perioperative nutritional support for GC patients may be a new method of improving patient outcomes. Multivariate analysis indicated that the T stage, N stage, pathological grade and PNI were independent risk factors for survival after radical gastrectomy. These results further show that the preoperative PNI may be superior to traditional inflammatory indicators as a potential indicator of the prognosis of patients after radical gastrectomy.

The limitations of this study are as follows: First, the study was a retrospective analysis, and the sample size is small; large-scale, multicenter, prospective studies should be designed. Second, we were not able to collect data on indicators of systemic infections in our research, such as the level of CRP, so we cannot rule out systemic inflammation or the effect of stress on the conclusions of this paper. Because this study was a retrospective study, we only collected data on the patients\' survival, but did not have access to complete and effective data on disease-free survival. Therefore, it was not possible to analyze these important prognostic indicators. Finally, the follow-up time was relatively, and a study with a longer-term follow-up period should be designed. In future studies, we will further address the deficiencies.
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![The value of various inflammatory markers in the survival of patients after GC radical resection. The area under the curve of PNI is significantly higher than that of NLR and LMR. PNI, prognostic nutritional index; NLR, neutrophil-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio.](mco-12-03-0196-g00){#f1-mco-0-0-1980}

![Prognostic K-M curve of PNI and gastric cancer. The postoperative survival rate of patients with PNI \<46.03 was significantly lower than that of patients with PNI ≥46.03. The difference between the two groups is statistically significant. PNI \<46.030-(102) and PNI ≥46.030-(68). PNI, prognostic nutritional index.](mco-12-03-0196-g01){#f2-mco-0-0-1980}

###### 

Comparison of the receiver operating curves of inflammation indicators.

  Parameter   AUC     95% CI        Cut-off   Sensitivity (%)   Specificity (%)   Z-value   P-value
  ----------- ------- ------------- --------- ----------------- ----------------- --------- -----------------------------------------------------
  PNI         0.725   0.623-0.826   46.03     77.14             69.69             \-        \-
  NLR         0.609   0.507-0.712   2.464     80.00             45.93             2.228     0.026^[a](#tfn1-mco-0-0-1980){ref-type="table-fn"}^
  LMR         0.609   0.510-0.708   3.279     80.00             48.15             2.714     0.006^[a](#tfn1-mco-0-0-1980){ref-type="table-fn"}^

^a^P\<0.05. PNI, prognostic nutritional index; NLR, neutrophil-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; AUC, area under the curve; CI, confidence interval.

###### 

General clinical characteristics of patients with gastric cancer.

  Parameter                 PNI\<46.03 (n=102)   PNI≥46.03 (n=68)   χ^2^/F   P-value
  ------------------------- -------------------- ------------------ -------- --------------------------------------------------------
  Sex                                                                         
       Male                 82                   45                           
       Female               20                   23                 4.3630   0.0367^[a](#tfn2-mco-0-0-1980){ref-type="table-fn"}^
  Age (years)                                                                 
       \<60                 35                   28                           
       ≥60                  67                   40                 0.8238   0.3641^[a](#tfn2-mco-0-0-1980){ref-type="table-fn"}^
  Recent weight loss (kg)                                                     
       \<5                  63                   46                           
       ≥5                   39                   22                 0.6136   0.4334^[a](#tfn2-mco-0-0-1980){ref-type="table-fn"}^
  Histological type                                                           
       Adenocarcinoma       82                   63                           
       Other                20                   5                  4.8851   0.0271^[a](#tfn2-mco-0-0-1980){ref-type="table-fn"}^
  Tumor location                                                              
       Gastric cardia       44                   22                           
       Gastric body         27                   18                           
       Gastric antrum       31                   28                 2.5892   0.2740^[b](#tfn3-mco-0-0-1980){ref-type="table-fn"}^
  Tumor size (cm)                                                             
       \<5                  43                   41                           
       ≥5                   59                   27                 5.3691   0.0205^[a](#tfn2-mco-0-0-1980){ref-type="table-fn"}^
  T stage                                                                     
       T1-T2                6                    9                            
       T3-T4                96                   59                 2.7421   0.0977^[a](#tfn2-mco-0-0-1980){ref-type="table-fn"}^
  N stage                                                                     
       N0-N1                33                   44                           
       N2-N3                69                   24                 17.241   \<0.0001^[a](#tfn2-mco-0-0-1980){ref-type="table-fn"}^
  Pathological stage                                                          
       I-II                 20                   33                           
       III                  82                   35                 15.911   \<0.0001^[a](#tfn2-mco-0-0-1980){ref-type="table-fn"}^
  NLR                                                                         
       \<2.464              40                   61                           
       ≥2.464               62                   7                  43.131   \<0.0001^[a](#tfn2-mco-0-0-1980){ref-type="table-fn"}^
  LMR                                                                         
       \<3.279              63                   9                            
       ≥3.279               39                   59                 12.581   0.0004^[a](#tfn2-mco-0-0-1980){ref-type="table-fn"}^

P-values were determined using a

^a^χ^2^ test and

^b^ANOVA. PNI, prognostic nutritional index; NLR, neutrophil-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio.

###### 

Univariate analysis and multivariate analysis of the 5-year survival of patients after radical gastrectomy.

                            Univariate analysis   Multivariate analysis                                      
  ------------------------- --------------------- ----------------------- --------- ------- ---------------- -------
  Sex                                                                                                         
       Male                 127                   16.3                                                        
       Female               43                    17.6                    0.728     \-      \-               \-
  Age (years)                                                                                                 
       \<60                 63                    17.5                                                        
       ≥60                  107                   15.9                    0.204     \-      \-               \-
  Recent weight loss (kg)                                                                                     
       \<5                  109                   17.4                                                        
       ≥5                   61                    15.6                    0.214     \-      \-               \-
  Histological type                                                                                           
  Adenocarcinoma            145                   17.1                                                        
       Other                25                    15.2                    0.136     \-      \-               \-
  Tumor location                                                                                              
       Gastric cardia       66                    15.75                                                       
       Gastric body         45                    14.7                                                        
       Gastric antrum       59                    27.4                    0.007     0.821   (0.663-1.016)    0.070
  Tumor size (cm)                                                                                             
       \<5                  84                    20.45                                                       
       ≥5                   86                    14.75                   \<0.001   1.026   (0.705-1.494)    0.892
  T stage                                                                                                     
       T1-T2                15                    77.6                                                        
       T3-T4                155                   15.7                    \<0.001   5.267   (1.878-14.770)   0.002
  N stage                                                                                                     
       N0-N1                77                    47.8                                                        
       N2-N3                93                    12.7                    \<0.001   1.731   (1.036-2.895)    0.036
  Pathological stage                                                                                          
       I-II                 53                    72.5                                                        
       III                  117                   14.1                    \<0.001   8.386   (4.415-15.929)   0.000
  NLR                                                                                                         
       \<2.464              101                   20.6                                                        
       ≥2.464               69                    14.6                    0.005     \-      \-               \-
  LMR                                                                                                         
       \<3.279              72                    15.15                                                       
       ≥3.279               98                    21.05                   0.003     \-      \-               \-
  PNI                                                                                                         
       \<46.03              102                   14.8                                                        
       ≥46.03               68                    27.5                    \<0.001   1.513   (1.015-2.256)    0.042

^a^Adjusted for the following variables: Tumor location, tumor size, T stage, N stage, pathological stage and PNI. PNI, prognostic nutritional index; NLR, neutrophil-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; MST, median survival time; CI, confidence interval.

[^1]: Abbreviations: PNI, prognostic nutritional index; NLR, neutrophil-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; AUC, area under the curve; MST, median survival time; CI, confidence interval
